Cargando…

New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children

Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity disorder (ADHD). Longer-acting stimul...

Descripción completa

Detalles Bibliográficos
Autores principales: Domnitei, Diana, Madaan, Vishal
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877609/
https://www.ncbi.nlm.nih.gov/pubmed/20520740
_version_ 1782181787903983616
author Domnitei, Diana
Madaan, Vishal
author_facet Domnitei, Diana
Madaan, Vishal
author_sort Domnitei, Diana
collection PubMed
description Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity disorder (ADHD). Longer-acting stimulants are thus considered as first-line for management of ADHD symptoms. Over the years, concerns about the abuse potential of stimulants have led to the development of alternative formulations of these agents. One such recent development, lisdexamfetamine (LDX) was FDA approved for treating ADHD in children in early 2007 and in adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to l- lysine and active d-amphetamine, which is responsible for its therapeutic activity. This unique formulation may lead to a possible reduction of the abuse potential, by bypassing the first-pass metabolism. In fact, a statistically significant difference for the ‘liking’ effects on the Drug Questionnaire Response has been reported with intravenous LDX compared to d-amphetamine. LDX appears to have an efficacy and tolerability profile comparable to other extended-release stimulant formulations used to treat ADHD, but reduced potential for abuse-related liking effects when compared to equivalent amounts of immediate-release d-amphetamine. The most common adverse events include decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea.
format Text
id pubmed-2877609
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28776092010-06-02 New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children Domnitei, Diana Madaan, Vishal Neuropsychiatr Dis Treat Expert Opinion Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity disorder (ADHD). Longer-acting stimulants are thus considered as first-line for management of ADHD symptoms. Over the years, concerns about the abuse potential of stimulants have led to the development of alternative formulations of these agents. One such recent development, lisdexamfetamine (LDX) was FDA approved for treating ADHD in children in early 2007 and in adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to l- lysine and active d-amphetamine, which is responsible for its therapeutic activity. This unique formulation may lead to a possible reduction of the abuse potential, by bypassing the first-pass metabolism. In fact, a statistically significant difference for the ‘liking’ effects on the Drug Questionnaire Response has been reported with intravenous LDX compared to d-amphetamine. LDX appears to have an efficacy and tolerability profile comparable to other extended-release stimulant formulations used to treat ADHD, but reduced potential for abuse-related liking effects when compared to equivalent amounts of immediate-release d-amphetamine. The most common adverse events include decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea. Dove Medical Press 2010-05-25 2010 /pmc/articles/PMC2877609/ /pubmed/20520740 Text en © 2010 Domnitei and Madaan, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Expert Opinion
Domnitei, Diana
Madaan, Vishal
New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_full New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_fullStr New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_full_unstemmed New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_short New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_sort new and extended-action treatments in the management of adhd: a critical appraisal of lisdexamfetamine in adults and children
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877609/
https://www.ncbi.nlm.nih.gov/pubmed/20520740
work_keys_str_mv AT domniteidiana newandextendedactiontreatmentsinthemanagementofadhdacriticalappraisaloflisdexamfetamineinadultsandchildren
AT madaanvishal newandextendedactiontreatmentsinthemanagementofadhdacriticalappraisaloflisdexamfetamineinadultsandchildren